Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
2B3-101
DRUG
2 trials
Sponsors
BBB-Therapeutics B.V.
, The Netherlands Cancer Institute
Conditions
Brain Metastases
Breast Cancer
Lung Cancer
Malignant Glioma
Melanoma
Meningeal Carcinomatosis
Phase 1
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Completed
NCT01386580
BBB-Therapeutics B.V.
Brain Metastases, Breast Cancer, Lung Cancer +2
Start: 2011-07-31
End: 2014-12-31
Updated: 2015-01-22
Phase 2
Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases
NCT01818713
The Netherlands Cancer Institute
Meningeal Carcinomatosis
Start: 2013-10-31
End: 2014-10-31
Target: 6
Updated: 2013-10-29
Related Papers
Abstract P6-16-04: Phase 1/2a study of glutathione PEGylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases
Cancer Research
2015-05-01
5 citations
Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma
Cancer Research
2014-10-01
37 citations